Detrol LA In Men With Overactive Bladder.
Public ClinicalTrials.gov record NCT00282932. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double Blind, Placebo Controlled Detrol LA "Add-On" To Alpha-Blocker Study In Men With Persistent Overactive Bladder Symptoms Of Urinary Frequency And Urgency With/Without Urgency Incontinence After Previous Monotherapy With Alpha Blocker.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
An interventional active/placebo double blinded parallel randomized controlled study in which at 12 weeks of treatment, the primary endpoint of patient perception of bladder condition is measured along with associated safety and other secondary endpoints like bladder diary endpoints, quality of life and patient treatment satisfaction. Patients included in the study must have symptoms of OAB (frequency of at least 8 per day and Urgency of at least 1 episode per day confirmed by bladder diary). Patients are not eligible to enroll in the study if they have/had significant hepatic or renal disease, history of radiation treatment.
Study identification
- NCT ID
- NCT00282932
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 600 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 40 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 2006 (Type not available)
- Primary completion
- May 1, 2007 (Actual)
- Completion
- May 14, 2007 (Actual)
- Last update posted
- Jan 27, 2021
2006 – 2007
United States locations
- U.S. sites
- 11
- U.S. states
- 10
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Anaheim | California | 92801 | — |
| Pfizer Investigational Site | La Mesa | California | 91942 | — |
| Pfizer Investigational Site | Aurora | Colorado | 80012 | — |
| Pfizer Investigational Site | Iowa City | Iowa | 52242-1089 | — |
| Pfizer Investigational Site | Shreveport | Louisiana | 71106 | — |
| Pfizer Investigational Site | Watertown | Massachusetts | 02472 | — |
| Pfizer Investigational Site | Woodlane | New Jersey | 08060 | — |
| Pfizer Investigational Site | New York | New York | 10016 | — |
| Pfizer Investigational Site | Cincinnati | Ohio | 45212 | — |
| Pfizer Investigational Site | State College | Pennsylvania | 16801 | — |
| Pfizer Investigational Site | Houston | Texas | 77024 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 70 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00282932, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 27, 2021 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00282932 live on ClinicalTrials.gov.